A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandramohan, Vidyalakshmi, Bigner, Darell D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912004/
https://www.ncbi.nlm.nih.gov/pubmed/24498557
http://dx.doi.org/10.4161/onci.26852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912004/
https://www.ncbi.nlm.nih.gov/pubmed/24498557
http://dx.doi.org/10.4161/onci.26852

Ejemplares similares